Drugs / REGN7041
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07218770 | Dec 2025 → Jun 2028 expected | posterior uveitis | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN7041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07218770 ↗ |
| Modality | Monoclonal antibody | “REGN7041 (Anti-CD3 Monoclonal Antibody)” NCT07218770 ↗ |